Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 4:25 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,075 matching trials from the live ClinicalTrials.gov search.
Conditions
COVID-19
Interventions
Aluminum Hydroxide Suspension, Boost-2867, CpG 7909, Sodium Chloride, 0.9%
Drug · Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 64 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
8
States / cities
San Francisco, California • Baltimore, Maryland • St Louis, Missouri + 5 more
Conditions
COVID-19
Interventions
Povidone-Iodine 2%, Povidone-Iodine 0.5%, Isotonic saline 0.9%
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Stanford, California
Active, not recruiting Not applicable Interventional

tVNS in Long COVID-19

NCT06585254
Conditions
Long COVID, Chronic Fatigue Syndrome
Interventions
Transcutaneous vagus nerve stimulator
Device
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
21 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
New York, New York
Conditions
Corona Virus Infection, Coronavirus
Interventions
imPulse™ Una e-stethoscope, Philips Lumify Ultrasound System
Device
Lead sponsor
Level 42 AI, Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Baltimore, Maryland
Terminated Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Adults at High Risk of SARS-CoV-2 Exposure

NCT04642638
Conditions
Coronavirus Infection, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), COVID-19 Disease
Interventions
INO-4800, CELLECTRA® 2000, Placebo
Drug · Device
Lead sponsor
Inovio Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,307 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
16
States / cities
Chandler, Arizona • Phoenix, Arizona • Tempe, Arizona + 12 more
Conditions
Covid19
Interventions
ATI-450, Placebo
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Kansas City, Kansas
Terminated No phase listed Observational Accepts healthy volunteers

Vaccine Observation to Include All Communities for Equitable Science

NCT04770649
Conditions
Vaccine Response Impaired, Vaccine Adverse Reaction
Interventions
COVID-19 vaccine
Biological
Lead sponsor
Persephone Biosciences
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
San Diego, California
Conditions
COVID 19, Rehabilitation, Inpatient, Hospitalized
Interventions
Tele-exergaming Tablet
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Houston, Texas
Completed Not applicable Interventional Results available

Vagus Nerve Stimulation as Treatment for Long Covid

NCT05608629
Conditions
Long COVID, Chronic Fatigue Syndrome
Interventions
Transcutaneous Non-Invasive Vagus Nerve Stimulation
Device
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
Up to 70 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
New York, New York
Conditions
SARS-CoV, SARS-CoV-2
Interventions
VXCO-100
Biological
Lead sponsor
Vaccine Company, Inc, a wholly owned subsidiary of Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
3
States / cities
Decatur, Georgia • Baltimore, Maryland • Rochester, New York
Conditions
Corona Virus Infection, SARS-CoV Infection, Coronavirus
Interventions
Hydroxychloroquine, Placebo oral tablet
Drug
Lead sponsor
McGill University Health Centre/Research Institute of the McGill University Health Centre
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Long COVID, Long Covid19
Interventions
Narrative Intervention for Long COVID-19 (NICO)
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 89 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Aurora, Colorado
Terminated Phase 1 Interventional Results available

Camostat With Bicalutamide for COVID-19

NCT04652765
Conditions
Covid19, SARS-CoV Infection, Coronavirus Infection
Interventions
Camostat Mesilate, Bicalutamide 150 mg
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
60 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Respiratory Tract Diseases, Influenza (Pandemic), Influenza, Community Acquired Pneumonia, Community Acquired Pneumonia (CAP), Community Acquired Pneumonia, Severe, COVID-19, Respiratory Tract Infection Acute, Respiratory Tract Infections (RTI), SARS CoV 2 Infection
Interventions
Ceftriaxone + Macrolide, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam + Macrolide, Ceftaroline + Macrolide, Amoxicillin-clavulanate + Macrolide, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, P2Y12 inhibitor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Angiotensin Receptor Blockers, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Remdesivir, Nirmatrelvir/ritonavir + remdesivir, Amoxicillin-clavulanate + Ceftazidime + Macrolide, Meropenem + Macrolide
Drug · Other · Biological + 1 more
Lead sponsor
UMC Utrecht
Other
Eligibility
28 Days and older
Enrollment
20,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2029
U.S. locations
11
States / cities
Jacksonville, Florida • Augusta, Georgia • Chicago, Illinois + 8 more
Conditions
SARS-CoV-2
Interventions
Enhanced Preservation Media (EPM-IX)
Diagnostic Test
Lead sponsor
Convergent Genomics, Inc.
Network
Eligibility
18 Years and older
Enrollment
205 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Chicago, Illinois
Completed No phase listed Observational Accepts healthy volunteers Results available

COVID-19 Observational Research Collaboratory

NCT05394025
Conditions
COVID-19, SARS-CoV-2 Infection
Interventions
Not listed
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
479 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
6
States / cities
West Haven, Connecticut • Ann Arbor, Michigan • Durham, North Carolina + 3 more
Conditions
COVID-19
Interventions
Exercise Prescription
Other
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Frisco, Texas
Conditions
Respiratory Distress Syndrome, Adult
Interventions
Veru-111
Drug
Lead sponsor
Veru Inc.
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
5
States / cities
Scottsdale, Arizona • Saint Louis Park, Minnesota • Saint Paul, Minnesota + 2 more
Conditions
COVID-19
Interventions
MPV/S-2P
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 64 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
3
States / cities
Decatur, Georgia • Mineola, New York • Houston, Texas
Completed Not applicable Interventional Results available

Rapid, Onsite COVID-19 Detection

NCT04460690
Conditions
COVID-19, Sars-CoV2
Interventions
Rapid Onsite COVID-19 Detection
Device
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
5 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
COVID-19, Acute Respiratory Distress Syndrome, SARS-CoV-2, Hypoxemia
Interventions
Rejuveinix (RJX) Active Comparator, Placebo Comparator
Drug
Lead sponsor
Reven Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
3
States / cities
Houston, Texas • New Braunfels, Texas
Conditions
SARS-COV2 Virus
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Year to 90 Years
Enrollment
730 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Bethesda, Maryland • Pittsburgh, Pennsylvania
Conditions
Coronavirus Infection
Interventions
INO-4800, CELLECTRA® 2000
Drug · Device
Lead sponsor
Inovio Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
3
States / cities
Lexington, Kentucky • Kansas City, Missouri • Philadelphia, Pennsylvania
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults

NCT05827926
Conditions
SARS-CoV-2, Influenza
Interventions
Influenza Vaccine 1, mRNA-1083.1, mRNA-1083.2, mRNA-1083.3, Investigational Influenza Vaccine 1, Investigational COVID-19 Vaccine 1, COVID-19 Vaccine 1, Investigational Influenza Vaccine 2, Influenza Vaccine 2, mRNA-1083, Investigational COVID-19 Vaccine 2, COVID-19 Vaccine 2
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years to 79 Years
Enrollment
1,758 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
69
States / cities
Chandler, Arizona • Colton, California • Huntington Beach, California + 59 more